In this video, Michael Wang, MD, University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of a Phase II Window-2 clinical trial, which analyzed the safety and efficacy of ibrutinib, rituximab and venetoclax in patients with mantle cell lymphoma (MCL) (NCT03710772). Dr Wang briefly explains the impressive responses observed in the patient cohorts in this trial, and the importance of transitioning from a chemotherapy-based regimen to a chemotherapy-free regimen in the treatment of newly diagnosed MCL. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.